Synaptogenix is focused on developing innovative therapeutics aimed at restoring cognitive function in patients suffering from neurodegenerative diseases and developmental disorders. Central to their approach is Bryostatin-1, a compound that promotes neuronal health and synaptic regeneration. The company has successfully completed two Phase II pilot studies, demonstrating clinically meaningful cognitive restoration and the regeneration of cerebral connections. Their research emphasizes the importance of synapses in cognitive functioning, as synaptic loss is a significant factor in conditions like Alzheimer's disease. Synaptogenix collaborates with prestigious institutions such as the National Cancer Institute and the National Institutes of Health, leveraging extensive funding and expertise to advance their therapeutic pipeline.

The company's therapeutic strategies are designed to address a range of serious conditions, including Alzheimer's disease, Fragile X Syndrome, multiple sclerosis, Parkinson's disease, traumatic brain injury, and stroke. Synaptogenix's management team boasts over 30 years of experience in drug development, particularly with Bryostatin and related platform drugs. Their research highlights the activation of protein kinase C (PKC) as a mechanism for enhancing cognitive function and preventing synaptic loss, which is crucial for effective neuronal communication. By focusing on the restoration of synaptic health, Synaptogenix aims to provide meaningful improvements in the quality of life for patients affected by debilitating neurological disorders.

United States

Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease

Synaptogenix

Company Details